Monoclonal antibodies are a growing class of biological agents for the treatment of a variety of diseases. Scientists are now looking at ways to modify their structure, to optimize their function within the body. This includes conjugating small molecular inhibitors to antibodies, so that the combined molecule can deliver the active ingredient to a highly specific site within the body.
Random42 developed this medical animation for Amgen Oncology to highlight their new antibody drug conjugate technology.
‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.’’
Product Manager, GSK
‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.’’
Oncology Clinical Liaison, Bristol-Myers Squibb
‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics
‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen